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Abstract

Author Manuscript

Fetal alcohol spectrum disorders (FASD) are caused by ethanol exposure during the pregnancy and
is the leading cause of mental retardation. Ethanol exposure during the development results in the
loss of neurons in the developing brain, which may underlie many neurobehavioral deficits
associated with FASD. It is important to understand the mechanisms underlying ethanol-induced
neuronal loss and develop appropriate therapeutic strategies. One of the potential mechanisms
involves neuroimmune activation. Using a third trimester equivalent mouse model of ethanol
exposure, we demonstrated that ethanol induced a wide-spread neuroapoptosis, microglial
activation, and neuroinflammation in C57BL/6 mice. Minocycline is an antibiotic that inhibits
microglial activation and alleviates neuroinflammation. We tested the hypothesis that minocycline
may protect neurons ethanol-induced neuron death by inhibiting microglial activation and
neuroinflammation. We showed that minocycline significantly inhibited ethanol-induced caspase-3
activation, microglial activation, and the expression of pro-inflammatory cytokines. In contrast,
minocycline reversed ethanol inhibition of anti-inflammatory cytokines. Minocycline blocked
ethanol-induced activation of GSK3β, a key mediator of neuroinflammation and microglial
activation in the developing brain. Consistent with the in vivo observations, minocycline inhibited
ethanol-induced the expression of pro-inflammatory cytokines and activation of GSK3β in a
microglia cell line (SIM-9). GSK3β inhibitor eliminated ethanol activation of pro-inflammatory
cytokines in SIM-9 cells. Co-cultures of cortical neurons and SIM-9 microglia cells sensitized
neurons to alcohol-induced neuronal death. Minocycline protected neurons against ethanolinduced neuronal death in neurons/microglia co-cultures. Together, these results suggest that
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minocycline may ameliorate ethanol neurotoxicity in the developing by alleviating GSK3βmediated neuroinflammation.

Keywords
Apoptosis; development; fetal alcohol syndrome; inflammation; microglia; neurodegeneration

Introduction

Author Manuscript

Ethanol exposure during pregnancy may cause fetal alcohol spectrum disorders (FASD)
which are characterized by a spectrum of structural anomalies and neurocognitive and
behavioral disabilities (Riley et al., 2011). Fetal Alcohol Syndrome (FAS) is the most severe
form of FASD and displays the complete phenotype of characteristic intrauterine growth
restriction, central nervous system (CNS) malformations, mental retardation, and
craniofacial and skeletal defects. The incidence of FASD in the United States is between 2
and 5% (May et al., 2009). FASD represent the leading cause of mental retardation in North
America (K. et al., 2008; May and Gossage, 2001). Ethanol affects divers developmental
events at all stages ranging from neurogenesis to myelination (Saito et al., 2016; Yang and
Luo, 2015; Young et al., 2008). Among them, permanent depletion of neurons is the most
devastating effect. Despite attempts to increase public awareness of the risks involved, the
number of women drinking during pregnancy has not declined in the USA (Ebrahim et al.,
1999; Surveys, 2013). It is therefore important to understand the mechanisms underlying
ethanol-induced neuron death and develop strategies prevent or ameliorate alcohol-induced
CNS damages.

Author Manuscript

It is well established that neuroinflammation plays an important role in alcohol use disorder
(AUD) (Crews et al., 2017). Recently findings indicate that ethanol induces neuroimmune
activation in the developing brain as well. Microglia, the resident macrophages, are the
mediator of neuroinflammation in the CNS, and it has been proposed that ethanol could
activate microglial and induce proinflammatory molecules which impair neuronal survival
and function, leading to long-term neuropathological and cognitive defects observed in
FASD (Chastain and Sarkar, 2014; Drew and Kane, 2014; Kane and Drew, 2016).

Author Manuscript

Minocycline, a second generation broad-spectrum antibiotic, is a tetracycline derivative that
is capable of crossing the blood brain barrier (BBB). It is frequently postulated to be a
“microglia inhibitor” (Moller et al., 2016) and has a potent anti-microglial activation and
anti-inflammatory property. Minocycline has been shown to protect neurons in various
neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD),
cerebral ischemia, spinal cord injury (Budni et al., 2016; Chen et al., 2012; Cox et al., 2015;
Dheen et al., 2007; Seidl and Potashkin, 2011). In this study, we tested the hypothesis that
minocycline may protect neurons ethanol-induced neuron death by inhibiting microglial
activation and neuroinflammation in the developing brain. We used a well-established third
trimester equivalent mouse model in which ethanol produces a wide-spread
neurodegeneration in the developing brain. We showed that minocycline effectively inhibited
ethanol-induced microglial activation/neuroinflammation and ameliorated
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neurodegeneration. It appears that minocycline may target AKT/GSK3β-mediated
neuroinflammation in microglia.

Material and Methods
Reagents

Author Manuscript

Minocycline was purchased from Sigma Chemical Co. (St. Louis, MO, USA). TRIzol was
purchased from Life Technologies (Gaithersburg, MD, USA). Anti-MCP-1 and anti-CD68
antibodies were purchased from Bio-Rad AbD Serotec, Inc. (Raleigh, NC, USA). AntiCCR-2 antibody was purchased from BioVision, Inc. (Milpitas, CA, USA). Anti-Iba-1
antibody was purchased from Wako Chemicals USA, Inc. (Richmond, VA, USA). AntiOX-42 antibody was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). All
other antibodies were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA).
Other reagents used in this project were obtained from Sigma-Aldrich, Inc (St. Louis, MO,
USA) unless stated otherwise.
Animals and ethanol exposure

Author Manuscript

C57BL/6J mice were obtained from Jackson Laboratory (Bar Harbor, Maine, USA). All
animals were housed in a specific pathogen-free room within the animal facilities at the
University of Kentucky, and were handled according to the Institutional Animal Care and
Use Committee, University of Kentucky. Minocycline and ethanol were administrated on
postnatal day 5 (PD5). Pups were weighed, toe-clipped, and randomly assigned to 4 groups:
control, minocycline, ethanol, and ethanol plus minocycline. Minocycline was dissolved in
PBS and administered by two subcutaneous (SC) injections at a concentration of 15 mg/kg
or 30 mg/kg each at 12 and 2 hours prior to ethanol exposure. The concentrations of
minocycline were selected based on previous studies in rodents investigating the
neuroprotection of minocycline (Beheshti Nasr et al., 2013; Kobayashi et al., 2013). We
injected minocycline before ethanol exposure to ensure the minocycline inhibition of
microglial activation. Pups received a total of 5 g/kg ethanol in two SC injections; each
consisted of 2.5 g/kg and was 2 hours apart (Alimov et al., 2013; Ikonomidou et al., 2000;
Olney et al., 2002). Pups were returned to the dam immediately following each injection.
Control animals received SC injections of the same volume of sterile saline. At 8 hours after
the first ethanol injection, pups were sacrificed for and processed for neurochemical and
molecular analyses
Culture and treatment of microglial cells and neurons

Author Manuscript

Immortalized mouse microglia cells (SIM-A9) were purchased from American Type Culture
Collection (ATCC) (Manassas, VA, USA). SIM-A9 cells are a spontaneously immortalized
microglial cell line cloned from mouse cerebral tissues of C57BL6 mice. They have
phenotypic and functional properties characteristic of primary microglia and are capable of
switching their profiles to pro- or anti-inflammatory phenotypes in response to exogenous
stimuli (Nagamoto-Combs et al., 2014). SIM-A9 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM)/F12 medium supplemented with 5% heat-inactivated
horse serum, 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin at 37°C in 5% CO2 in a humidified atmosphere. At
Neuropharmacology. Author manuscript; available in PMC 2019 February 01.
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80–90% confluence, the culture medium was replaced with DMEM/F12 medium containing
0.1% FBS overnight before indicated treatment. The cultures were exposed to ethanol
(0.2%, 0.4%, or 0.8%) in sealed containers. The containers were placed in a humidified
environment and maintained at 37°C with 5 % CO2. With this method, the ethanol
concentration in the culture medium can be accurately maintained (Luo and Miller, 1997).
For minocycline treatment, cells were exposed to minocycline (50 μM) 2 hours prior to
ethanol treatment as previously described (Song et al., 2008).

Author Manuscript

Primary cortical neurons were generated from the brain of C57BL6 mice on postnatal day 1.
The method for the isolation and culture of primary cortical neuronal has been previously
described in detail (Chen et al., 2016; Wang et al., 2007). Briefly, the pups were decapitated
and the brain immediately transferred into dissection medium (97.5% Hank’s balanced salt
solution, 0.11 mg/ml sodium pyruvate, 0.1% glucose, 10 mM HEPES, 100 U/ml penicillin,
and 100 μg/ml streptomycin). The meninges were removed and the cerebral cortices
dissected. Cerebral cortical tissues were dissociated with 0.25% trypsin for 15 min at 37 °C
followed by 0.1% DNase treatment for 5 min. Then, tissues were carefully triturated and the
cell suspension was mixed with 4% bovine serum albumin and centrifuged. The cell pellet
was resuspended in Neuronbasal/B27 medium containing B27 (2%), glutamine (1 mM/L),
penicillin (100 U/ml) and streptomycin (100 μg/ml). Cells were plated onto poly-D-lysine
(50 μg/ml)-coated cell culture wells or dishes and maintained at 37°C in a humidified
environment containing 5% CO2 for 7 days before the initiation of experiment.

Author Manuscript

The co-cultures of microglia cells and primary cortical neurons were established in 24-well
cell culture plates with inserts as described previously (Ock et al., 2010; Wang et al., 2015a).
The cortical neurons were maintained in the cell culture plate containing 500 μl of medium
at a density of 2.5 ×107 cells/well. SIM-A9 cells were grown in the culture insert (0.2 μm
pore size) in a separate plate at a density of 6 × 106 cells/per insert in 200 μl of medium.
SIM-A9 cells were cultured overnight at 37°C and 5% CO2, then treated with minocycline at
50 μM for 30 min. After that, the inserts containing SIM-A9 cells were placed into the wells
containing the cortical neurons. The co-cultures were then treated with ethanol with or
without minocycline for 48 hours. The viability of neurons was determined by the 3-(4,5dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously
described (Wang et al., 2007).
Immunoblotting

Author Manuscript

After treatment, mice were anesthetized by intraperitoneal injection of ketamine/xylazine
and the cerebral cortices, cerebella, and the rest of brain were immediately dissected from
four groups of mice. The tissues were frozen in liquid nitrogen and stored at −80°C. The
proteins in brain tissues or SIM-A9 cells were extracted using previously described method
with some modification (Wang et al., 2007). Briefly, tissues or cells were homogenized and
lysed in an ice-cold lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM
EGTA, 1 mM PMSF, 0.5% NP-40, 0.25% SDS, 5 μg/ml leupeptin, and 5 μg/ml aprotinin.
Homogenates were centrifuged at 20,800 x g for 30 min at 4°C and the supernatant fractions
were collected. The protein concentration in the supernatant was determined
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The procedure for immunoblotting has been previously described (Wang et al., 2007).
Briefly, aliquots of proteins (50 μg) were loaded into the lanes of a sodium dodecyl sulfatepolyacrylamide gel. The proteins were separated by electrophoresis and transferred to
nitrocellulose membranes. The membranes were blocked with 5% BSA in 0.01 M Trisbuffered saline (TBS) (pH 7.4) and 0.05% Tween-20 (TBST) at room temperature for 1
hour, then incubated with primary antibodies directed against target proteins overnight at
4°C. The final dilutions for primary antibodies were: anti-cleaved caspase-3 antibody,
1:1,000; anti-phospho-GSK3β (Ser9) antibody, 1:1,000; phospho-GSK3β (Tyr216)
antibody, 1:1,000; anti-MCP-1 antibody, 1:500; anti-CCR-2 antibody, 1:1,000; anti-CD-68
antibody, 1:1,000; anti-OX-42 antibody, 1:1,000; anti-phospho-Akt (Ser473) antibody,
1:1000; anti-phospho-Akt (Thr308) antibody, 1:1,000; anti-active β-catenin antibody,
1:1000; anti-phospho-CREB antibody, 1:1,000; and anti-phospho-c-Jun antibody, 1:500.
After two quick washes in TBST, the membranes were incubated with secondary antibodies
conjugated to horseradish peroxidase (Amersham, Arlington, Heights, IL) diluted at 1:5, 000
in TBST containing 5% BSA for 1 hour. The immunocomplexes were detected by the
enhanced chemiluminescence method (Amersham). The density of immunoblotting was
quantified with the software of ImageJ (version 1.48; National Institutes of Health,
Bethesda, MD).
Quantitative real-time PCR
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Total RNA was extracted from brain tissues samples which were stored in liquid nitrogen or
SIM-A9 cells using TRIzol reagent as previously described (Yang et al., 2012). RNA
concentration was determined by spectrophotometric optical density measurement at 260
and 280 nm. The ratio 260 nm and 280 nm (OD260/280) was used estimate the purity of the
nucleic acid. OD260/280 in all samples ranged between 1.7 and 2.0. The cDNA synthesis was
performed using High-Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA)
according to the manufacturer’s protocol. Quantitative real-time PCR (qRT-PCR) was
performed using ABI 7500 Real-Time PCR system (Applied Biosystems). 18S RNA was
used as an internal control. Results were expressed as mean fold changes of gene expression
relative to control group using 2−ΔΔCT method.
Immunohistochemistry

Author Manuscript

The procedure for immunohistochemistry (IHC) has been previously described (Wang et al.,
2015a). Briefly, mice were deeply anesthetized by intraperitoneal injection of ketamine/
xylazine and then intracardially perfused with PBS followed by 4% paraformaldehyde in
PBS (pH 7.4). The brain tissues were removed, post fixed in 4% paraformaldehyde for
additional 24 hours and then transferred to 30% sucrose in PBS until the brain sunk to the
bottom. Sagittal brain sections (20–40 μm) were cut on a freezing microtome. Floating
sections were permeabilized with 0.1% Triton X-100 in PBS, incubated in 0.3% H2O2/50%
methanol in PBS for 10 min. After washing with PBS, sections were mounted on slides and
dried. The slides were blocked with 5% normal goat serum containing 0.5% Triton X-100 in
PBS for 1 hour at room temperature, and then incubated with primary antibodies (diluted in
PBS with 1% BSA) overnight at 4°C. The dilution for the primary antibodies was: anticleaved caspase-3 antibody, 1:6,000; and anti-Iba1 antibody, 1:1,000. After washing with
PBS, slides were incubated with a biotin-conjugated goat anti-rabbit secondary antibody
Neuropharmacology. Author manuscript; available in PMC 2019 February 01.
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(1:1,000) for 1 hour at room temperature and followed by washing with PBS. Avidin-biotinperoxidase complex was prepared according to the manufacturer’s instructions. The slides
were incubated in the complex for 1 hour at room temperature. After rinsing, the slides were
developed in 0.05% 3, 3′-diaminobenzidine (DAB) containing 0.003% H2O2 in PBS.
Statistical analysis
The data were expressed as mean ± SEM. All analyses were performed using the SPSS
software (SPSS, Chicago, IL, USA). Differences in indicated protein expression, mRNA
expression, or cell viability in experimental groups were determined by the one-way
Analysis of Variance (ANOVA). Differences in which the p value was less than 0.05 were
considered statistically significant. In cases where significances were detected, specific post
hoc comparisons between treatment groups were examined with Student-Newman-Keuls
tests or Dunnett’s T3 tests.

Author Manuscript

Results
Minocycline blocks ethanol-induced caspase-3 activation in the developing brain

Author Manuscript

First, we sought to determine whether minocycline offer protection against ethanol-induced
neuronal death in the developing brain. We used a well-established mouse model of
postnatal ethanol exposure (Carloni et al., 2004; Ikonomidou et al., 2000; 2001; Olney et al.,
2002; Young et al., 2005; 2008). As shown in Fig. 1A, the alterations in cleaved caspase-3
were analyzed by one-way ANOVA with the treatments as a variable. A significant alteration
in cleaved caspase-3 was observed in the cortex (F(3,36)=21.12; p <0.05), cerebellum
(F(3,36)=16.21; p <0.05), and other parts of brain (F(3,36)=32.54; p <0.05). Ethanol exposure
caused a drastic increase in cleaved caspase-3 in the cerebral cortex, cerebellum, and other
parts of brain (p <0.05). However, minocycline treatment significantly diminished ethanolinduced caspase-3 activation (p <0.05). For the saline-injected control and minocycline
treatment alone, there was little caspase-3 activation. The results from the immunoblotting
analysis were confirmed by the IHC study (Fig. 1B). Ethanol induced a wide-spread
expression of cleaved caspase-3 in the cerebral cortex, midbrain, thalamus, anterior olfactory
nucleus, and cerebellum. Minocycline treatment drastically reduced the immunoreactivity of
cleaved caspase-3. We examined the time course of the effect of minocycline on cleaved
caspase-3, Bax and Iba-1 (Fig. 1C). At each time points we examined minocycline reduced
ethanol-induced expression of cleaved caspase-3, Bax and Iba-1; minocycline at 15 mg/kg
and 30 mg/kg offered similar protection.
Minocycline alleviates ethanol-induced inflammation in the developing brain

Author Manuscript

To confirm that minocycline reduced ethanol-induced neuroinflammation, we examined the
expression of a number of pro-inflammatory as well as anti-inflammatory cytokines/
chemokines in the developing brain. Inerleukin-6 (IL-6) is a pro-inflammatory cytokine that
plays multiple roles in central nervous system (CNS) during infections and injuries
(Vallieres and Rivest, 1999; Wang et al., 2015b). As shown in Fig. 2A, a significant
alteration in IL-6 mRNA was observed in the cortex (F(3,28)=15.08; p <0.05), the cerebellum
(F(3,28)=3.89, p <0.05), and other part of brains (F(3,28)=3.44, p <0.05). Ethanol significantly
increased the mRNA level of IL-6 in the cortex, cerebellum, and other parts of brain,

Neuropharmacology. Author manuscript; available in PMC 2019 February 01.

Wang et al.

Page 7

Author Manuscript

compared with the control group (p <0.05) (Fig. 2A). While minocycline alone had little
effect on the basal level of IL-6 mRNA (p >0.05), it inhibited ethanol-induced increase of
IL-6 mRNA compared with ethanol group (p <0.05) (Fig. 2A). In contrast to its effect on
IL-6, ethanol’s effect on Ym1, an anti-inflammatory marker (Roszer, 2015), was complex.
One-way ANOVA revealed statistically significant alterations in the cortex (F(3,28)=6.15, p
<0.05), the cerebellum (F(3,28)=5.16, p <0.05), and other brain parts (F(3,28)=4.29, p <0.05).
Ethanol significantly reduced the mRNA level of Ym1 by 30% and 48% in the cerebellum
and other parts of the brain (p <0.05), respectively, but significantly increased it by 80% in
the cortex (p <0.05), compared control group. Minocycline in combination with ethanol
increased the expression of Ym1 (p <0.05), compared with the ethanol-treated group.
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Monocyte chemoattractant protein-1 (MCP1, also known as CCL2) and its receptor (CCR-2)
are pro-inflammatory mediators and up-regulated in many CNS disorders (Dimitrijevic et
al., 2007; Hinojosa et al., 2011; Yao and Tsirka, 2014). In the cortex, both minocycline or
ethanol treatment alone increased the expression of MCP-1 and CCR-2 protein; however,
when they were applied together, minocycline significantly inhibited ethanol-induced
increase in MCP-1 and CCR-2 protein levels (Fig. 2B): For MCP-1, F(3,36)=43.24, p <0.05;
for CCR-2, F(3,28)=8.23, p <0.05; for CD68, F(3,28)=23.05, p <0.05; for OX42,
F(3,28)=18.78, p <0.05. In the cerebellum, ethanol significantly increased the expression of
both MCP-1 and CCR-2 (p <0.05), while minocycline only significantly increased MCP-1 (p
<0.05), but not CCR-2 expression, compared with the control group (Fig. 2C). As in the
cortex, minocycline significantly inhibited ethanol-induced increase in MCP-1 and CCR-2
protein levels (p <0.05), compared with the ethanol group. In the other part of brain, ethanol
only significantly increased the expression of MCP1 (p <0.05), but not CCR-2, compared
with the control group; minocycline alone did not affect their expression (Fig. 2D).
Minocycline significantly inhibited ethanol-induced expression of MCP-1 and significantly
reduced the CCR-2 expression below basal levels (p <0.05), compared with ethanol group
(Fig. 2D). Therefore, in general, minocycline inhibited ethanol-induced expression of proinflammatory cytokines/chemokines, but increased anti-inflammatory markers.
Minocycline inhibits ethanol-induced microglial activation in the developing brain

Author Manuscript

Microglial activation plays a key role in the neuroinflammation associated with many CNS
disorders (Dheen et al., 2007). Since minocycline is a “microglia inhibitor”, we sought to
determine whether minocycline was able to inhibit ethanol-induced microglial activation.
Both CD68, a cell surface marker of M1-poalrized microglia, and OX42 (CD11b), a major
adhesion receptor of neutrophils, are inflammatory markers in the brain and indicative of
microglial activation (Jeong et al., 2013; Kobayashi et al., 2013). In the cortex, ethanol
significantly increased the expression of CD68 and OX42 (p <0.05), compared with control
group; while pretreatment of minocycline blocked ethanol-induced increase of these proteins
(p <0.05), compared with ethanol group (Fig. 2B). A similar observation was obtained in the
cerebellum (Fig. 2C). In the other part of brain, minocycline blocked ethanol-induced
increase in OX42 (p <0.05), compared with ethanol group (Fig. 2D). Although minocycline
and ethanol alone did not alter the expression of CD68, they acted together to significantly
reduced its expression below the basal levels (p <0.05), compared with control group.
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Microglial activation was further assessed morphologically by IHC of Iba-1. Iba-1 is
expressed in both active and resting microglia and used as a microglial marker. The resting
microglia cell is characterized by a small cell body and much elaborated thin processes,
which send multiple branches and extend in all directions, while the activated microglia have
fewer and thicker processes with larger cell body (Chen et al., 2012). Ethanol significantly
increased the number of active microglia (p <0.05), compared with the control group;
minocycline significantly inhibited ethanol-induced activation of microglia, (p <0.05),
compared with ethanol group (Fig. 3).
Minocycline inhibits ethanol-induced GSK3β activation in the developing brain
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Glycogen synthase kinase 3 beta (GSK3β) plays an important role in neuroinflammation and
microglial activation (Maixner and Weng, 2013). The dysregulation of GSK3β contributes to
the development and progression of many neurological diseases through regulating the
neuroinflammation processes (Golpich et al., 2015; Maixner and Weng, 2013; Sandberg et
al., 2014; Verdile et al., 2015). Inhibitors of GSK3β have been shown to be beneficial in
many various models of neuroinflammatory diseases including Alzheimer’s disease,
multiple sclerosis, and AIDS dementia complex (Maixner and Weng, 2013). The activity of
GSK3β is mainly regulated by the phosphorylation at serine 9 which results in the inhibition
of GSK3β (Golpich et al., 2015; Luo, 2009; Maixner and Weng, 2013). As shown in Fig.
4A, co-treatment with minocycline significantly increased the expression of GSK3β in the
cortex (F(3,36) = 30.45; p <0.05), the cerebellum (F(3,36) = 50.97; p <0.05), and other parts of
brain (F(3,36) = 26.86; p <0.05). Ethanol significantly decreased the expression of
phosphorylated GSK3β [p-GSK3β (Ser9)] by 72%, 49%, and 73% in the cortex,
cerebellum, and other parts of the brain, respectively, compared with the control group (p
<0.05) (Fig. 4A), indicating an activation of GSK3β. Minocycline blocked ethanol’s
inhibitory effect on p-GSK3β (Ser9) by increasing the levels of p-GSK3β (p <0.05) in the
cortex, cerebellum, and other parts of brain (Fig. 4A). The activity of GSK3β can also be
positively regulated by the phosphorylation at tyrosine 216 (Medina and Wandosell, 2011).
Our results showed that neither ethanol nor minocycline affected expression of total GSK3β
and p-GSK3β (Tyr216) in the developing brain (data not shown).
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We then examined the effect of ethanol on the upstream and downstream components of
GSK3β. AKT is upstream of GSK3β and the activation of AKT results in the inhibition of
GSK3β through inducing its phosphorylation at serine 9 (Zhang et al., 2003). β-catenin is a
substrate of GSK3β which induces its degradation through destabilizing it; activation of
GSK3β destabilizes β-catenin while inactivation of GSK3β increases the stabilized (nonphosphorylated) form of β-catenin, resulting in higher levels of β-catenin (Zhu et al., 2009).
AKT/GSK3β/β-catenin signaling plays a critical role in neuroinflammation and
neurodegeneration (Kitagishi et al., 2012; Orellana et al., 2015; Zhao et al., 2012). AKT
activation involves the phosphorylation of two residues: threonine 308 (Thr308) in the
activation loop and serine 473 (Ser473) in the C-terminal hydrophobic motif. In general,
ethanol inhibited AKT phosphorylation (p <0.05), compared with the control group, and
minocycline abolished ethanol inhibition of AKT phosphorylation (p <0.05), compared with
the ethanol group (Fig. 4B). Ethanol and minocycline did not affect the levels of total AKT
(data not shown). Similarly, ethanol decreased the expression of the active form of β-catenin
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(p <0.05), compared with the control group, and minocycline restored the levels of β-catenin
in the cortex and cerebellum to the controls. In other parts of brain, minocycline
significantly increased the levels of p-AKT(T308) and active form of β-catenin over the
control group (p <0.05) (Fig. 4B).
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Since p38 MAPK and JNKs are other important mediators of microglial activation and
neuroinflammation in the brain (Badshah et al., 2016; Dheen et al., 2007; Zhao et al.,
2016b), we investigated the effect of ethanol on these signaling pathways. Ethanol had little
effect on p38 MAPK (data not shown) but increased the phosphorylation of c-Jun (p-c-Jun),
the substrate of JNKs in the cortex, cerebellum, and other parts of brain (Fig. 5).
Phosphorylated c-Jun contributes to the formation of the activator protein 1 (AP-1)
transcription factor complex which is involved in the expression of many pro-inflammatory
genes and cytokines, such as IL-6 and TNF-α (Zhao et al., 2016a). p-c-Jun is also one of the
GSK3β target proteins (Luo, 2009). Minocycline blocked ethanol-induced increase in p-cJun (Fig. 5).
Minocycline inhibits ethanol-stimulated pro-inflammatory cytokines in cultured microglial
cells

Author Manuscript

We used a mouse microglia cell line, SIM-A9 to assess the direct effect of ethanol and
minocycline on microglia in the context of minocycline neuroprotection. We first
investigated the effect of ethanol on SIM-A9 cells. Ethanol rapidly increased the mRNA
levels of IL-6 (F(3, 16)=35.17, p <0.05), TNF-α (F(3, 16)=42.31, p <0.05), IL1b (F(3, 16)=7.51,
p <0.05), MCP-1 (F(3, 16)=4.87, p <0.05), and NOS2 (F(3, 16)=67.85, p <0.05) in SIM-A9
cells (Fig. 6A). The increase in IL-6, TNF-α, and IL1b mRNA peaked at 1 hour after
ethanol exposure (p <0.05), compared with the control group. The increase in MCP-1 and
NOS2 mRNA peaked at 3 and 6 hours after ethanol exposure (p <0.05), respectively,
compared with the control group (Fig. 6A). Minocycline blocked ethanol-induced increase
in the expression of IL-6, TNF-α, IL1b, MCP-1, and NOS2 at 1.5 hours after ethanol
exposure (p <0.05), compared with the ethanol group (Fig. 6B).
Minocycline inhibits ethanol-induced GSK3β activation in cultured microglial cells

Author Manuscript

Then, we examined the role of GSK3β in ethanol-induced inflammation and the effect of
minocycline on microglial cells. Ethanol activated GSK3β by decreasing p-GSK3β (Ser9) in
a concentration- and duration-dependent manner in SIM-A9 cells (p <0.05), compared with
the control group (Fig. 7A). As a result, ethanol caused a concentration- and durationdependent decrease of active β-catenin (p <0.05), compared with the control group. As
observed in vivo, ethanol also decreased the level of p-AKT (Ser473), but increased p-c-Jun
in SIM-A9 cells (Fig. 7A) (p <0.05), compared with the control group. Minocycline
inhibited ethanol-induced GSK3β activation and decrease in active β-catenin levels (p
<0.05), compared with the ethanol group; it blocked ethanol-mediated alterations in p-AKT
(Ser473) and p-c-Jun (p <0.05), compared with the ethanol group (Fig. 7B).
Blocking GSK3β inhibits ethanol-stimulated pro-inflammatory in microglial cells
To determine the role of GSK3β in ethanol-induced inflammation, we used a GSK3β
inhibitor, lithium to inhibit the activity of GSK3β in SIM-A9 cells. Previous studies has used
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lithium to evaluate the role of ethanol-induced neuronal death in vitro and in vivo (Luo,
2010; Young et al., 2008; Zhong et al., 2006). As shown in Fig. 8, lithium alone significantly
decreased the intrinsic mRNA levels of IL-6, TNF-α, IL1b, MCP-1, and NOS2 in
comparison with the no treatment controls (p <0.05). More importantly, lithium eliminated
ethanol-induced increase in mRNA levels of IL-6, TNF-α, IL1b, MCP-1, and NOS2 (p
<0.05), compared with the ethanol group (Fig. 8). These data suggested that the GSK3β
played an important a role in microglia-mediated inflammation.
Minocycline protects neurons against ethanol-induced neuronal death in the co-culture of
mouse cortical neurons and microglia cells

Author Manuscript

To investigate the role of microglial activation on ethanol-induced neuronal death we used a
co-culture system in which mouse cortical neurons and SIM-A9 cells were cultured together.
In primary cortical neuron cultures alone, ethanol caused significant but relatively modest
decrease in cell viability 17.0% (F(3,16)=4.63, p <0.05) (Fig. 9). In the co-culture system,
ethanol caused more decrease in neuronal viability around 32.4% (F(3,16)=12.47, p <0.05).
Minocycline significantly ameliorated ethanol-induced neuronal death in the co-cultures;
ethanol plus minocycline only reduced neuronal viability by 17.6% (p <0.05), compared
with the control group. In primary cortical neuron cultures alone, minocycline offered little
protection (data not shown). These results suggested that microglia contributed to ethanolinduced neuronal death and minocycline protection was, at least in part, mediated through
the inhibition of microglial activation.

Discussion
Author Manuscript

This study used a well-established third trimester equivalent mouse model of ethanol
exposure to demonstrate the neuroprotective role of minocycline. Minocycline inhibits
ethanol-induced caspase-3 activation, microglial activation, and the expression of proinflammatory factors. Minocycline reverses ethanol inhibition of anti-inflammatory
cytokines and blocks ethanol-induced activation of GSK3β, a key mediator of
neuroinflammation/microglial activation in the developing brain. Using an in vitro
microglial model, we demonstrate that GSK3β mediates ethanol-stimulated proinflammatory cytokines in cultured microglial cells and minocycline blocks ethanol-induced
activation of GSK3β as well as the increase in pro-inflammatory factors. Furthermore,
minocycline protects primary cortical neurons against ethanol-induced neuronal death in
neurons/microglia co-cultures. This is the first to show that minocycline can ameliorate
ethanol-induced apoptotic neurodegeneration in the developing brain, implying a potential
therapeutic role of minocycline.
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The mechanisms underlying ethanol-induced neuronal death in the developing brain are
complex; it may be mediated by the interference with signaling by neurotrophic factors,
disruption of microRNAs (miRNAs), oxidative stress, endoplasmic reticulum (ER) stress
(Boyadjieva and Sarkar, 2013a; Luo, 2012; Miranda, 2012; Yang and Luo, 2015).
Neuroinflammation plays important role in both alcohol use disorders (AUD) and FASD
(Chastain and Sarkar, 2014; Kane and Drew, 2016; Crews et al., 2017). There is extensive
evidence showing that ethanol activate microglia in experimental models of AUD and FASD
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(Chastain and Sarkar, 2014; Kane and Drew, 2016; Saito et al., 2016; Wilhelm and Guizzetti,
2015). Microglial activation is often categorized into pro-inflammatory (M1), antiinflammatory (M2), and intermediate phenotypes (Kane and Drew, 2016; Saito et al., 2016;
Zhao et al., 2016b). M1 microglia may contribute to dysfunction of the neurotrophic system
by producing pro-inflammatory cytokines, such as tumor necrosis factor-α (TNFα), IL-1β,
IL-6, iNOS, and CCL2, usually leading to neurotoxicity. The M2 phenotype, sometimes
called the neuroprotective microglial phenotype, enhances clearance of debris and produces
anti-inflammatory mediators including Ym1, arignase1 (Arg1), IL-4, IL-10, and TGFβ to
antagonize inflammation-induced damage in the CNS (Zhao et al., 2016b). In our model
system, ethanol-induced microglial activation appears to be associated with an increase in
pro-inflammatory cytokines and chemokines, suggesting that ethanol promotes M1-like
phenotype of microglia. The ethanol-induced microglial activation appears transient. In
SIM-A9 cells, ethanol induces a rapid increase in pro-inflammatory factors within hours and
then declines (Fig. 6A).
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Minocycline, a second-generation tetracycline with anti-inflammatory and anti-apoptotic
property, has high lipid solubility (Good and Hussey, 2003) and readily crosses blood-brain
barrier (Saivin and Houin, 1988; Yong et al., 2004). It has been tested for therapeutic
benefits in animal models of various CNS diseases (Garrido-Mesa et al., 2013). Minocycline
was shown to be beneficial in several neurological disorders, such as multiple sclerosis and
spinal cord injury, stroke and traumatic injury, and some several neurodegenerative
conditions including Parkinson’s disease, Huntington’s disease, amyotrophic lateral
sclerosis, and Alzheimer’s disease (Budni et al., 2016; Chen et al., 2000; Choi et al., 2007;
Du et al., 2001; Garrido-Mesa et al., 2013). The main biological effects of tetracycline are
inhibition of microglial activation, attenuation of apoptosis, and suppression of reactive
oxygen species production (Orsucci et al., 2009). In humans, long-term treatment with
minocycline is generally safe and well tolerated (Garrido-Mesa et al., 2013). However,
minocycline may have some toxic effects especially for developing brain depending on
animal models, route/dosage, and timing of administration (Zhu et al., 2014; Arnoux et al.,
2014; Hanlon et al., 2017; Majidi et al., 2016; Strahan et al., 2017). In our paradigm,
minocycline dis not have apparent toxic effects on the CNS. Minocycline inhibits ethanolinduced microglial activation in the developing brain (Fig. 3). Generally, minocycline
inhibits ethanol-stimulated pro-inflammatory cytokines but increases the expression of antiinflammatory factors (Fig. 2). These findings are verified by in vitro studies which
demonstrate that minocycline inhibits ethanol-induced pro-inflammatory factors in cultured
microglial cells (Fig. 6), suggesting that minocycline attenuates microglia-mediated
neuroinflammation. More importantly, minocycline provides a dramatic protection against
ethanol-induced apoptotic neurodegeneration in wide-spread brain regions of PD5 mice
(Figs. 1–2). The positive correlation between its neuroprotective role and inhibition of
microglial activation/neuroinflammation suggests that minocycline may alleviate ethanol
neurotoxicity by blocking microglia-mediated neuroinflammation. Furthermore, our study
using a neurons/microglia co-culture system indicates that ethanol is more toxic for primary
cortical neurons in the presence of microglial cells and minocycline offers a significant
neuroprotection in this co-culture system (Fig. 9). Together, these results suggest that
ethanol-induced microglial activation/neuroinflammation may be harmful for the developing
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neurons in our model system and minocycline protects neurons by attenuating microgliamediated neuroinflammation. The view that microglia-mediated neuroinflammation
contributes neurotoxicity in the developing brain is supported by many both in vitro and in
vivo studies (Chastain and Sarkar, 2014). Particularly, Boyadjieva and Sarkar (2013) showed
that the conditioned media collected from ethanol-activated microglial enhanced apoptotic
death of cultured fetal hypothalamic neurons probably through the ROS and proinflammatory cytokines presented in the conditioned media.
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However, microglial activation may also have a regenerative and neuroprotective role
ethanol exposure (Chastain and Sarkar, 2014; Saito et al., 2016). It is believed that transient
activation of microglia may be a response to neuronal damage and results in phagocytosis of
degenerating neurons; while phagocytosis of pathogens requires initiation of an
inflammatory response, removal of apoptotic neurons by microglia may prevent excessive
inflammation and offer protection (Saito et al., 2016). For example, systemic administration
of lipopolysaccharide (LPS), an agonist of TLR4 prior to ethanol exposure in PD7 mice,
activates microglia and causes neuroinflammation in the developing brain, and attenuates
ethanol-induced neurodegeneration (Saito et al., 2016). The evidence suggests that activation
of microglia may offer neuroprotection in the neonatal brain. We show that ethanol increases
the expression of CD68, a marker for phagocytes (Fig. 2), suggesting that these microglia
are phagocytes engulfing degenerating neurons. However, minocycline inhibits the
expression of CD68, which does not support that phagocytosis of degenerating neurons is
sufficient to provide neuroprotection.
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Ethanol-induced microglial activation may be either a secondary response to neuronal
damage and/or results from a direct effect on microglia. It is difficult to distinguish these
effects in animal studies. We therefore used an in vitro microglia model (SIM-A9) to
evaluate the direct effect of ethanol and minocycline on microglial cells. We show that
ethanol can directly affect microglial cells and induce the expression of pro-inflammatory
factors in these cells (Fig. 7). This finding is supported by previous studies showing that
ethanol can direct activate microglia in culture (Boyadjieva and Sarkar, 2013b; Liu et al.,
2012; Liu et al., 2009; Yang et al., 2014). GSK3β and p38 MAPK are two key intracellular
signaling components mediating microglia activation and neuroinflammation (Wang et al.,
2010; Badshah et al., 2016). In our model system, ethanol has little effect on p38 MAPK
(data not shown) and therefore we focused on GSK3β. GSK3β is critical mediator of ethanol
neurotoxicity and ethanol activates GSK3β in neurons in the developing brain (Luo, 2009,
2012). Ethanol activates GSK3β by inhibiting p-GSK3β (Ser9) in the developing brain;
over-expression of GSK3β makes neurons more sensitive to ethanol while inhibition of
GSK3β protects neurons against ethanol-induced neurodegeneration in vitro and in vivo (Liu
et al., 2009). Lithium, a GSK3β inhibitor, protects neurons against ethanol-induced
neurodegeneration and inhibition of neurite outgrowth (Chen et al., 2012; Liu et al., 2009).
The current study confirms the previous observation and expands it to microglial cells (Fig.
7). The ethanol-induced activation of GSK3β in microglial cells may be mediated by its
inhibition of AKT, an upstream signaling component (Fig. 7). The role of GSK3β in
ethanol-induced neuroinflammation is further demonstrated by that lithium blocks ethanolinduced expression of pro-inflammatory factors (Fig. 8). Minocycline inhibits ethanolinduced activation of GSK3β in the developing brain (Fig. 4) and cultured microglial cells
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(Fig. 7); the effect may result from the activation of upstream AKT. It remains to be
determined whether minocycline also inhibits ethanol-induced GSK3β activation in neurons.
Since GSK3β activation is involved in pro-apoptotic pathways in neuron and microgliamediated neuroinflammation, it is conceivable that lithium-mediated protection may result
from its inhibition of GSK3β in both neurons and microglia. Although lithium is a GSK3β
inhibitor, it may protect developing brain against ethanol-induced neuroapoptosis through
modulating other signaling pathways, such as the activation of ERK pathway (Young et al.,
2008).
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Effects of ethanol on pro-inflammatory signaling appear not limited to the AKT/GSK3β
pathway. c-Jun N-terminal kinases (JNK) are also important mediator of microglia-mediated
neuroinflammation (Badshah et al., 2016). We show that ethanol activates JNKs which is
evident by the increases of their substrate, phosphorylated c-Jun, and more importantly
minocycline inhibits ethanol-induced p-c-Jun (Fig. 5). Other investigators also show that
ethanol activates the JNK system. However, JNK activation does not occur in the same
neuronal populations that are killed by ethanol (Young et al., 2008). The exact role of JNK
system in ethanol-induced microglial activation and neuroapoptosis remains to be
investigated. In addition to intracellular signaling components, microglia can be activated
through transmembrane receptors, such as Toll-like receptor 4 (TLR4) by ethanol directly or
indirectly (Saito et al., 2016). Future study will need to determine the effect of ethanol and
minocycline on TLR4 activation.
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In this paradigm, ethanol-induced neuroapoptosis is accompanied by the activation of
intrinsic apoptotic pathway, such as upregulation/release of Bax, Bad, and cytochrome C
(Ikonomidou et al., 2000; Olney et al., 2002). We confirm that ethanol activates the intrinsic
apoptotic pathway (Fig, 1C). Although the current findings indicate that the inhibition
microglial activation is involved in minocycline’s protective effect, we do not conclude that
the inhibition microglial activation is the sole pathway for minocycline’s protective effect.
Minocycline may directly act on neurons and offer protection. It would be interesting to
determine whether minocycline could protect adult brain against ethanol’s neurotoxicity.
Since some of ethanol’s effects are mediated by NMDA and GABA receptors, it would be
also interesting to examine whether minocycline could offset the toxicity of other NMDA
receptor antagonists and GABA receptor agonists.
In summary, this is the first study to show that minocycline offers protection against ethanolinduced neurotoxicity in the developing brain. Although our understanding of minocyclineinduced neuroprotection is incomplete, the inhibition of microglia-mediated
neuroinflammation is a potential mechanism.
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Abbreviation
AD

Alzheimer’s disease

CNS

central nervous system

CCR2
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FASD

fetal alcohol spectrum disorder

GSK3β

Glycogen synthase kinase 3 beta

Iba-1

ionized calcium binding adaptor molecule 1

IFN-γ

interferon γ

IHC

immunohistochemistry

IL

interleukin

MCP-1

monocyte chemoattractant protein-1

PD

Parkinson’s disease

TNF-α

tumor necrosis factor-α
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•

Minocycline inhibited ethanol-induced apoptosis and microglia activation in
the CNS

•

Ethanol activated GSK3β in the developing brain and cultured microglial
cells

•

GSK3β mediated microglial activation and was inhibited by minocycline

•

Minocycline protected neurons by inhibiting GSK3β-dependent
neuroinflammation
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Effect of minocycline on ethanol-induced apoptotic neuronal death in the developing mouse
brain. Pups of postnatal day 5 (PD5) were randomly assigned to 4 groups: control,
minocycline, ethanol, and ethanol with minocycline. Minocycline was administered by two
subcutaneous injections at a dose of 30 mg/kg each on 12 hour and 2 h before the ethanol
exposure. The Pups were exposed to ethanol by subcutaneous injections as described in the
Materials and Methods. Eight hours after ethanol injection, the pups were sacrificed. A: The
expression of cleaved caspase-3 in cortex, cerebellum, and other parts of the brain were
determined with immunoblotting. The expression of actin served as an internal control. The
relative amounts of cleaved caspaser-3 were quantified microdensitometrically and
normalized to the expression of actin. Each data point was the mean ± SEM of three
independent experiments. N = 10 for each group. *p < 0.05, statistically significant
difference from control group, #p < 0.05, statistically significant difference from ethanol
group. B: The expression of cleaved caspaser-3 was examined by immunohistochemistry
(IHC); bar = 100 μm. An image of higher magnification showed layers in the indicated brain
areas: 1. cortical retrosplenial; 2, cerebellum; 3. Periaqueductal gray. Bar= 1 mm. C: Mouse
pups were treated with minocycline (0, 15 mg/kg and 30 mg/kg) and ethanol as described
above. Mice were sacrificed at 4, 8, 12 hours after ethanol injection. The expression of
active-caspase, Bax and Iba-1 was determined and quantified. N = 6 for each group. *p <
0.05, statistically significant difference from control group, #p < 0.05, statistically significant
difference from ethanol group.
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Effect of minocycline on ethanol-induced inflammation. The treatment of minocycline and
ethanol was same as described in Fig. 1. A: The levels of mRNA for IL-6, a proinflammatory cytokine, and Ym-1, an anti-inflammatory cytokine in the cortex, cerebellum
and other part of brain were determined by qRT-PCR using 18s as an internal control.
Minocycline- or ethanol-induced changes were expressed as fold difference over the control.
Data are the mean ± SEM of three independent experiments. N = 8 for each group. *p <
0.05, statistically significant difference from control group, #p < 0.05, statistically significant
difference from ethanol group. B–D: The expression of MCP-1, CCR-2, CD-68 and OX42 in
cortex, cerebellum, and other parts of the brain were determined with immunoblotting. The
expression of actin served as an internal control. The relative amounts of indicated proteins
were quantified microdensitometrically and normalized to the expression of actin. Each data
point was the mean ± SEM of three independent experiments. n = 10 for each group. *p <
0.05, statistically significant difference from control group, #p < 0.05, statistically significant
difference from ethanol-treated group.
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Effect of minocycline on ethanol-induced microglia activation. The treatment of minocycline
and ethanol was same as described in Fig. 1. Microglia were identified by IHC of IBA-1 in
thalamus of brain area; bar = 200 μm. Images of higher magnification are shown in the lower
panel; bar = 100 μm). Activated microglia were determined morphologically and the number
of activated IBA-1 positive cells per mm2 was determined. Data are the mean ± SEM of
three independent experiments. *p < 0.05, statistically significant difference from control
group, #p < 0.05, statistically significant difference from ethanol group.
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Effect of minocycline on ethanol-induced GSK3β activation. The treatment of minocycline
and ethanol was same as described in Fig. 1. A: the expression of phospho-GSK3βSer9 (A)
was determined by immunoblotting. B: The expression of GSK3β upstream regulator AKT
(phospho-AKTSer473 and phospho-AKTThr308), and down-stream target, active β-catenin in
the cortex, cerebellum, and other parts of the brain was determined with immunoblotting.
The expression of actin served as an internal control. The relative amounts phosphoGSK-3βSer9, phospho-AKTSer473, phospho-AKTThr308, and active β-catenin were quantified
microdensitometrically and normalized to the expression of actin. Each data point was the
mean ± SEM of three independent experiments. *p < 0.05, statistically significant difference
from control group, #p < 0.05, statistically significant difference from ethanol group.
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Figure 5.

Effect of minocycline on ethanol-induced activation of JNKs. The treatment of minocycline
and ethanol was same as described in Fig. 1. The expression of phospho-c-Jun in the cortex,
cerebellum, and other parts of the brain were determined with immunoblotting. The
expression of actin served as an internal control.
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Figure 6.
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Effect of ethanol on the expression of cytokines and chemokines in microglia cells. A: SIMA9 microglial cells were exposed to ethanol (0.4 %) for 1, 3, and 6 hours. The mRNA levels
for IL-6, TNF-α, IL-1b, MCP-1, and NOS-2 were determined by quantitative PCR. B: SIMA9 cells were pretreated with minocycline (50 μM) for 2 hours, and then exposed to ethanol
(0.4%) for 1.5 hours. The mRNA levels of IL-6, TNF-α, IL-1b, MCP-1, and NOS-2 were
determined by quantitative PCR. Data are the mean ± SEM of three independent
experiments. *p < 0.05, statistically significant difference from control group, #p < 0.05,
statistically significant difference from ethanol-treated group.
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Figure 7.
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Effect of minocycline on ethanol-induced GSK3β activation in the microglia cells. A: SIMA9 were exposed to ethanol (0, 0.2%, 0.4, or 0.8%) for 6 hours. The expression of phosphoGSK-3βSer9, phospho-AKTSer473, phospho-c-Jun, and active β-catenin was determined by
immunoblotting. B: SIM-A9 cells were exposed to ethanol (0.4%) for 0, 1, 3, 6, or 12 hours.
The expression of phospho-GSK3βSer9, phospho-AKTSer473, phospho-c-Jun, and active βcatenin was determined by immunoblotting. C: SIM-A9 cells were pretreated with
minocycline (50 μM) for 2 hours, and then exposed to ethanol (0.4%) for 6 hour. The
expression of phospho-GSK3βSer9, phospho-AKTSer473, phospho-c-Jun, and active βcatenin was determined with immunoblotting. The expression of GAPDH served as an
internal control. The relative amounts phospho-GSK-3βSer9, phospho-AKTSer473, phosphoAKTThr308, phospho-c-Jun, and active β-catenin were quantified microdensitometrically and
normalized to the expression of GAPDH. Each data point was the mean ± SEM of three
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independent experiments. *p < 0.05, statistically significant difference from control
group, #p < 0.05, statistically significant difference from ethanol group.
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Figure 8.

Effect of GSK3β inhibitor on ethanol-induced inflammation in microglia cells. SIM-A9 cells
were pretreated with GSK3β inhibitor LiCl (10 mM) for 2 hours and exposed to ethanol
(0.4%) for 1.5 hour. The levels of mRNA for IL-6, TNF-α, IL-1b, MCP-1, and NOS-2 were
determined by qRT-PCR using 18s as an internal control. Ethanol- or LiCl-induced changes
were expressed as fold difference over the control. Data are the mean ± SEM of three
independent experiments. *p < 0.05, statistically significant difference from control
group, #p < 0.05, statistically significant difference from ethanol-treated group.
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Effect of minocycline on ethanol-induced neuronal death in co-cultures of mouse cortical
neurons and microglia. Co-cultures of SIM-A9 cells and primary cortical neurons were
established as described in the Materials and Methods. Co-cultures were exposed to ethanol
(0 or 0.4%) exposure with or without minocycline (50 μM) for 48 hours. The viability of
neurons was determined by MTT as described in the Materials and Methods. Data were the
mean ± SEM of three independent experiments. &p < 0.05, statistically significant difference
from cortical neuron alone; $p < 0.05, statistically significant difference from cortical neuron
with ethanol exposure; *p < 0.05, statistically significant difference from co-culture group
without ethanol; #p < 0.05, statistically significant difference from ethanol group in coculture. CN: Cortical neuron; CC: Co-culture.
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